A Dose Response Investigation of Docosahexaenoic Acid (DHA)

PHASE1CompletedINTERVENTIONAL
Enrollment

72

Participants

Timeline

Start Date

February 26, 2024

Primary Completion Date

February 26, 2025

Study Completion Date

March 26, 2025

Conditions
Nutrition, Healthy
Interventions
DIETARY_SUPPLEMENT

docosahexaenoic acid (DHA)

72 healthy participants will be divided into 6 groups and receive varying amounts of DHA (0mg, 100mg, 200mg, 400mg, 800mg and 1000mg) over the course of 8 weeks.

DIETARY_SUPPLEMENT

soybean oil placebo

72 healthy participants will be divided into 6 groups and receive varying amounts of DHA (0mg, 100mg, 200mg, 400mg, 800mg and 1000mg) over the course of 8 weeks. The 0mg group will receive only placebos.

Trial Locations (1)

M5C 2T2

Clinical Nutrition and Risk Factor Modification Centre, Toronto

All Listed Sponsors
collaborator

Unity Health Toronto

OTHER

lead

University of Toronto

OTHER

NCT06294067 - A Dose Response Investigation of Docosahexaenoic Acid (DHA) | Biotech Hunter | Biotech Hunter